Article info

Download PDFPDF
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case–control study

Authors

  • J Calvo-Alén Department of Medicine (Division of Clinical Immunology and Rheumatology), School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA; and the Department of Medicine (Division of Clinical Immunology and Rheumatology) PubMed articlesGoogle scholar articles
  • G McGwin Department of Surgery (Section of Trauma, Burns, and Critical Care), School of Medicine, The University of Alabama at Birmingham PubMed articlesGoogle scholar articles
  • S Toloza Department of Medicine (Division of Clinical Immunology and Rheumatology), School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA; and the Department of Medicine (Division of Clinical Immunology and Rheumatology) PubMed articlesGoogle scholar articles
  • M Fernández Department of Medicine (Division of Clinical Immunology and Rheumatology), School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA; and the Department of Medicine (Division of Clinical Immunology and Rheumatology) PubMed articlesGoogle scholar articles
  • J M Roseman Department of Epidemiology, School of Public Health, The University of Alabama at Birmingham PubMed articlesGoogle scholar articles
  • H M Bastian Department of Medicine (Division of Clinical Immunology and Rheumatology), School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA; and the Department of Medicine (Division of Clinical Immunology and Rheumatology) PubMed articlesGoogle scholar articles
  • E J Cepeda The University of Texas Health Science Center at Houston (Division of Rheumatology), Houston, Texas, USA PubMed articlesGoogle scholar articles
  • E B González The University of Texas Medical Branch at Galveston (Division of Rheumatology), Galveston, Texas PubMed articlesGoogle scholar articles
  • B A Baethge The University of Texas Medical Branch at Galveston (Division of Rheumatology), Galveston, Texas PubMed articlesGoogle scholar articles
  • B J Fessler Department of Medicine (Division of Clinical Immunology and Rheumatology), School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA; and the Department of Medicine (Division of Clinical Immunology and Rheumatology) PubMed articlesGoogle scholar articles
  • L M Vilá The University of Puerto Rico Medical Sciences Campus, Department of Internal Medicine (Division of Rheumatology), San Juan, Puerto Rico PubMed articlesGoogle scholar articles
  • J D Reveille The University of Texas Health Science Center at Houston (Division of Rheumatology), Houston, Texas, USA PubMed articlesGoogle scholar articles
  • G S Alarcón Department of Medicine (Division of Clinical Immunology and Rheumatology), School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA; and the Department of Medicine (Division of Clinical Immunology and Rheumatology) PubMed articlesGoogle scholar articles
  • for the LUMINA Study Group
    Google scholar articles
  1. Correspondence to:
    Dr Graciela S Alarcón
    830 Faculty Office Tower, 510 20th Street South, Birmingham, Alabama 35294-3408, USA; graciela.alarcon{at}ccc.uab.edu
View Full Text

Citation

Calvo-Alén J, McGwin G, Toloza S for the LUMINA Study Group, et al
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case–control study

Publication history

  • Accepted October 23, 2005
  • First published November 3, 2005.
Online issue publication 
May 12, 2006

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.